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Type 2 diabetes usually ensues from the inability of pancreatic beta cells to compensate for
incipient insulin resistance. The loss of beta cell mass, function, and potentially beta cell
identity contribute to this dysfunction to extents which are debated. In recent years, long
non-coding RNAs (lncRNAs) have emerged as potentially providing a novel level of gene
regulation implicating critical cellular processes such as pluripotency and differentiation.
With over 1000 lncRNAs now identiﬁed in beta cells, there is growing evidence for their
involvement in the above processes in these cells. While functional evidence on individual
islet lncRNAs is still scarce, we discuss how lncRNAs could contribute to type 2 diabetes
susceptibility, particularly at loci identiﬁed through genome-wide association studies as
affecting disease risk.
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INTRODUCTION
Diabetes is a major and growing health problem affecting 347 m
people worldwide (Danaei et al., 2011). Type 2 diabetes (T2D)
accounts for 90% of affected individuals, and is a complex, pro-
gressive disease affected by a range of genetic and environmental
risk factors. While insulin resistance plays a part in disease pro-
gression, pancreatic beta cell failure lies at the heart of T2D (Kahn,
2003).
Beta cells are the body’s sole source of circulating insulin, and as
such are critical for maintaining blood glucose within healthy lim-
its. The beta cell’s tightly regulated secretion of insulin in response
to glucose is dependent on a highly specialized metabolic sensing
system, underpinned by a speciﬁc pattern of gene expression. This
includes speciﬁc genes required for glucose-sensing (e.g., Gck and
Glut2), insulin production and processing (e.g., insulin, prohor-
mone convertase 1/3 [PC1/3]) and regulated secretion. Equally
important is the speciﬁc repression of genes which interfere with
proper regulation of insulin secretion (e.g., Slc16a1 and Ldha)
(Zhao et al., 2001; Pullen et al., 2012). Indeed, we (Pullen et al.,
2010) andothers (Thorrez et al., 2011) have recently identiﬁed∼40
“forbidden” or “disallowed” genes speciﬁcally repressed in islets
despite widespread expression across other tissues. While a unique
pattern of transcription factors (e.g., Pdx1, Pax6, MafA, Nkx2.2)
likely underlie the sustained expression of beta cell selective genes,
epigenetic mechanisms are vital for the mitotically stable main-
tenance of cellular identity and probably the suppression of
forbidden genes.
The tipping point from pre-diabetes to overt T2D is usually
reached when beta cells can no longer compensate sufﬁciently for
incipient insulin resistance. The nature of the progressive loss of
functional beta cell mass has been the source of some debate (Weir
and Bonner-Weir, 2013), with both decreases in overall beta cell
mass (Butler et al., 2003) and impaired glucose-stimulated insulin
secretion (GSIS) from the remaining islets being reported in T2D
subjects (Del Guerra et al., 2005). Indeed, recent work has sug-
gested that decreases in beta cell mass are modest (Rahier et al.,
2008) and may even have been over-estimated (Marselli et al.,
2014).
There has also been growing interest in a third option: that
a progressive loss of beta cell identity underlies the develop-
ment of T2D. Results from two rat models (Tokuyama et al.,
1995; Jonas, 1999), and the db/db mouse model (Kjorholt et al.,
2005) of T2D produce similar results showing a loss of dif-
ferentiated beta cells accompanied by similar changes in gene
expression: decreased expression of GSIS genes (e.g., Gck);
increased expression of normally repressed genes (e.g., Ldha and
Hk1); and decreases in islet transcription factors (e.g., Isl1, Neu-
rod1, Pdx1, and Pax6) (Tokuyama et al., 1995; Jonas, 1999).
The importance of these transcription factors in maintaining
beta cell identity is underscored by the transformation of beta
to alpha-like cells following Pdx1 deletion (Gao et al., 2014). In
FoxO1 knockout mouse islets, beta cells dedifferentiate a step fur-
ther, acquiring expression of immature endocrine cell markers
(Ngn3, Oct4, Nanog, and Mycl) (Talchai et al., 2012). However,
the relevance of this strain to human diabetic islets is as yet
unestablished.
While the relative importance of these three factors (impaired
beta cell mass, function and identity) in T2D is not fully
understood, mechanisms which increase beta cell function,
proliferation and identity are all sought to tackle the dis-
ease. Furthermore, increased understanding of the molecular
defects underlying T2D will enable novel therapies to address
the underlying causes of the disease, rather than just treat the
symptoms.
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A novel layer of gene regulation, acting partly through epi-
genetic mechanisms, was uncovered with the discovery that
thousands of long non-coding RNAs (lncRNAs) are expressed
from the genome (Guttman et al., 2009). lncRNAs are a diverse
group of transcripts deﬁned by a negative property: the lack of
protein-coding potential. They are differentiated from short ncR-
NAs such as miRNAs (which also play an important role: see Poy
et al., 2004; Guay et al., 2011; Pullen et al., 2011) by a minimum
length threshold of 200 nt. lncRNAs are often capped, spliced and
polyadenylated like mRNAs although both unspliced and non-
polyadenylated variants are also common. As a class, lncRNAs
are enriched in the nucleus relative to protein-coding transcripts,
although there remains a population of cytoplasmic-enriched
lncRNAs, and non-nuclear functions have been demonstrated for
a number of lncRNAs (Derrien et al., 2012). Indeed lncRNAs have
been demonstrated to regulate gene expression through a num-
ber of mechanisms at the transcriptional, post-transcriptional and
translational level.
The expression patterns of lncRNAs are signiﬁcantly more cell-
type speciﬁc than protein-coding genes (Guttman et al., 2009;
Djebali et al., 2012), making them well placed to play highly
cell-type speciﬁc roles. However, the fact that lncRNAs are
less evolutionarily conserved at the primary sequence level than
protein-coding genes and the fact the numerous lncRNAs appear
to be species-speciﬁc raise questions over their functions. lncRNAs
may depend more on secondary structure for their function, and
thus be more tolerant of mutations than protein-coding genes.
Indeed, lncRNA exons show evidence of low but clear sequence
conservation compared to other intergenic regions (Guttman
et al., 2009). The advent of next generation sequencing technolo-
gies has led to an explosion of novel lncRNA discovery in diverse
tissues, including pancreatic islets and beta cells. The discovery of
lncRNAs with the potential to regulate gene expression and cel-
lular identity in T2D-relevant tissues offers the opportunity for
greater understanding of disease etiology and novel targets for
treatment.
MECHANISMS OF lncRNA ACTION
miRNAs are amajor class of short non-codingRNAwhich primar-
ily act via a single, well-characterized mechanism to downregulate
gene expression through mRNA degradation and translational
inhibition. In contrast, lncRNAs have been shown to regulate gene
expression through a bewildering array of mechanisms (reviewed
extensively in Wang and Chang, 2011; Kung et al., 2013). On
average, lncRNAs are less abundant than protein-coding tran-
scripts, although some (e.g., H19) are expressed at comparable
levels (Djebali et al., 2012). lncRNAs are a heterogeneous group
of transcripts, and greater functional characterization will hope-
fully allow clearer classiﬁcation into distinct groups acting through
distinct mechanisms.
One of the ﬁrst identiﬁed modes of action of lncRNAs was
via alterations in chromatin modiﬁcations through recruiting
histone modifying complexes to particular genomic loci (Rinn
et al., 2007). This plays a major part in epigenetic silencing dur-
ing X-inactivation (through the lncRNA Xist (Zhao et al., 2008;
Pontier and Gribnau, 2011)) and at imprinted loci (e.g., Air at
the Slc22a3 locus (Nagano et al., 2008)). Indeed, this appears
to be a widespread function of lncRNAs, with around 20% of
intergenic lncRNAs identiﬁed in one study interacting with the
chromatin-modifying complex Polycomb Repressive Complex 2
(PRC2) (Khalil et al., 2009). In addition to affecting histone mod-
iﬁcations, lncRNAs can also act on the other major branch of
epigenetic regulation, DNA methylation, through interaction with
DNA methylation machinery (Mohammad et al., 2010; Di Rus-
cio et al., 2013). lncRNAs can further regulate gene expression by
mediating DNA looping (Lai et al., 2013). This affects the three-
dimensional conformation of chromosomes which regulates gene
expression by bringing distal enhancers physically adjacent to gene
promoters.
lncRNAs also act through a number of mechanisms to regulate
gene expression at the post-transcriptional level. Natural antisense
transcripts (NATs) are lncRNAs transcribed in the opposite orien-
tation to mRNAs with overlapping exons. They have the potential
for direct interaction with mRNAs through complimentary base-
pairing, which can increase mRNA stability (e.g., BASE1-AS and
BASE1) (Faghihi et al., 2008). In contrast, lncRNAs can also lead to
mRNA degradation through the recruitment of Staufen1 (STAU1)
(Gong and Maquat, 2011). lncRNAs can also inﬂuence mRNAs
indirectly by acting as “sponges” for miRNAs, preventing them
from downregulating gene expression (Kallen et al., 2013). It is
interesting to note that this last example refers to the highly
expressed H19 lncRNA, and these post-transcriptional mecha-
nisms presumably require lncRNAs in comparable abundance to
theirmRNAormiRNA targets. Given the lower expression of most
lncRNAs relative tomRNAs thesemechanisms requiring abundant
lncRNAs are perhaps the exception rather than the norm.
lncRNAs AND BETA CELL IDENTITY
As the expression of many lncRNAs is highly cell-type speciﬁc,
early catalogs of lncRNAs mainly from other cell lines provided
little information relevant to beta cells. However, a number of
studies have since identiﬁed lncRNAs genome-wide in human and
mouse, islets and beta cells.
Morán et al. (2012) used combination of ChIP-Seq (to iden-
tify sites of active transcription), and RNA-Seq (to directly detect
transcripts) to produce a comprehensive catalog of >1100 lncR-
NAs expressed in human islets. In agreement with studies in other
tissues, these lncRNAs proved to be signiﬁcantly more cell-type
speciﬁc than protein-coding genes. Indeed, 55% of intergenic
lncRNAs and 40% of antisense lncRNAs identiﬁed in this study
were speciﬁc to islets. Importantly, Morán et al. (2012) identiﬁed
several lncRNAs thatwere dysregulated in islets fromT2D subjects.
One challenge to the theory of widespread functions for lncR-
NAs is the low level of sequence conservation between species. To
address this, orthologous mouse genomic regions were detected
for 70% of human lncRNA loci, and RNA-Seq revealed that 47%
of these were actively transcribed in mouse islets (Morán et al.,
2012). Indeed this may be an underestimate as several lncR-
NAs were detected by qPCR despite falling below the threshold
for RNA-Seq detection. An independent transcriptomic study of
mouse islets identiﬁed a similar number (>1000) of intergenic
lncRNAs (Ku et al., 2012). Further dissection of islet cell-types
was performed by Bramswig et al. (2013), with the identiﬁcation
of ﬁve alpha cell-speciﬁc and twelve beta cell-speciﬁc lncRNAs.
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The scarcity of lncRNAs identiﬁed in this study may be due to
highly stringent removal of any transcripts overlapping repeat
regions.
Previous studies have identiﬁed both lncRNAs that regulate the
maintenance of pluripotency, and lncRNAs required for neuronal
differentiation (Ng et al., 2012). Indeed, the regulation of differen-
tiation and cell identity appears to be amajor function of lncRNAs.
Supporting this role for islet lncRNAs, Morán et al. (2012) identi-
ﬁed dynamic regulation of lncRNAs during in vitro differentiation
of human embryonic stemcells towards pancreatic endocrine cells.
As such protocols have thus far failed to produce fully functional
beta cells without an in vivo maturation stage in mice, perhaps
the most tantalizing discovery was six lncRNAs whose expression
was only activated during this last stage. Understanding regulators
of this critical maturation stage, and the ability to recapitulate it
without passage through animals would be essential for any ther-
apeutic generation of beta cells from human stem cells. However,
islet lncRNAs are not restricted to developmental roles, as deple-
tion of a beta cell-speciﬁc lncRNA was also shown to inﬂuence
gene expression in mature beta cells. Depletion of the lncRNA
HI-LNC25 decreased expression of the transcription factor and
monogenic diabetes gene, GLIS3 (Table 1) (Morán et al., 2012).
The location of HI-LNC25 and GLIS3 on separate chromosomes
(20 and 9, respectively) indicates that the lncRNA regulates GLIS3
in trans, although whether this is through a direct interaction with
this locus has not been explored.
lncRNAs IMPLICATED IN T2D SUSCEPTIBILITY
Within the last decade, genome-wide association studies (GWAS)
have been a major focus of work to identify the genetic vari-
ants underlying susceptibility to T2D and related metabolic traits.
Through identifying single nucleotide polymorphisms (SNPs)
which correlate with diabetic phenotypes, investigators aim to sin-
gle out genes which inﬂuence disease susceptibility. While much
of the interpretation of GWAS hits has focussed on protein-
coding genes, there are good reasons to indicate that lncRNAs
are responsible for the effects of some of these SNPs.
It is striking how few SNPs identiﬁed through GWAS for
T2D, indeed for most diseases, result in changes to protein
sequences. SLC30A8 is one of the few examples from early studies
where a SNP (rs13266634) resulted in an amino acid substitution
(R325W) affecting the zinc transporter located on insulin granules
(Sladek et al., 2007). Interestingly, expression of SLC30A8 is largely
restricted to pancreatic islets, so the effects of any mutations are
expected to be limited to the endocrine pancreas. In contrast, genes
at most other GWAS loci are more widely expressed. Missense
mutations at thesewidely expressed loci are farmore likely to cause
defects in multiple tissues and possibly embryonic lethality, which
could account for absence fromGWAS speciﬁc for T2Dand related
traits. In a more recent large-scale meta-analysis which aimed to
ﬁnely map the causal SNPs, only two of the 65 T2D susceptibility
loci examined had a lead SNP resulting in a missense mutation
(PPARG [rs1801282] and KCNJ11 [rs5215]) (Morris et al., 2012).
In both cases, rare severe mutations have previously been identi-
ﬁedwhich causemonogenic formsof diabetes (Barroso et al., 1999;
Gloyn et al., 2004). Most SNPs instead map to intronic or inter-
genic regions and thus likely act through altering gene expression
and/or splicing.
While the effects of changes to protein sequences are relatively
straightforward to investigate, it is often unclear which genes are
affected by SNPs in non-coding regions. Whereas proximal pro-
moters are directly adjacent to the genes they regulate, enhancer
elements can inﬂuence the expression of genes hundreds of kilo-
bases away, and can be interspersed between and even within other
genes (Ilnytska et al., 2009). Interestingly, SNPs associated with
T2D and fasting glycaemia are enriched in these distal regulatory
regions (Pasquali et al., 2014). The gene affected by SNPs falling
outside proximal promoters may not be clear, although the clos-
est gene is often used as a starting point for further investigation.
With the identiﬁcation and annotation of increasing numbers of
lncRNAs it has become apparent that a number of the GWAS hits
fall close to, or within lncRNAs.
Mapping SNPs at these 65 loci to current Ensembl annotations
shows ﬁve lead SNPs are within the exons or introns of lncRNAs
(Table 2). Two of these loci (KCNQ1 and CDKN2A/CDKN2B)
contain well characterized lncRNAs for which studies have started
to reveal the mechanisms through which they function. At the
PROX1 and PSMD6 loci, in both cases the lead SNP (rs2075423
and rs12497268) falls within the exon of an annotated anti-
sense orientated lncRNA. At the CCND2 locus, the lead SNP
(rs11063069) is approximately 9 kb upstream of the protein-
coding gene, yet within the intron of two antisense lncRNAs
(CCND2-AS1 andCCND2-AS2). Finally, as further islet-expressed
lncRNAs are identiﬁed more of these SNPs are found to fall closer
to lncRNAs than protein-coding genes (e.g., WFS1 locus (Morán
et al., 2012)).
KCNQ1
The KCNQ1 locus contains a number of genes with the poten-
tial to affect beta cell function and proliferation. Within this
locus KCNQ1, KCNQ1OT1, CDKN1C, PHLDA2, SLC22A18, and
SLC22A18AS are all expressed in both fetal pancreas and adult
islets (Travers et al., 2013). KCNQ1 encodes a voltage-gated potas-
sium channel subunit which is expressed in pancreatic beta cells
Table 1 |The main lncRNAs discussed in this paper along with their tissue and species specificity.
lncRNA Islet-specific expression Mouse ortholog identified Reference
HI-LNC25 Yes No Morán et al. (2012)
KCNQ1OT1 No Yes Travers et al. (2013)
CDKN2B-AS1 (ANRIL) No No – although a lncRNA has been
reported at the orthologous locus
Cunnington et al. (2010), Pasmant et al.
(2011), Visel et al. (2010)
www.frontiersin.org July 2014 | Volume 5 | Article 193 | 3
Pullen and Rutter Beta cell lncRNAs and diabetes
although its effect on the regulation of insulin secretion is some-
what unclear. siRNA knockdown of KCNQ1 in human islets
enhanced depolarization-induced exocytosis (Rosengren et al.,
2012), whereas pharmacological inhibition in INS-1 cells did not
affect basal, tolbutamide or GSIS (Ullrich et al., 2005). CDKN1C
encodes the p57KIP2 cyclin-dependent kinase inhibitor which is a
negative regulator of cell proliferation. It is expressed in islets, and
loss of p57KIP2 expression is associatedwith increasedbeta cell pro-
liferation in focal congenital hyperinsulinism (Kassem et al., 2001;
Henquin et al., 2011). PHLDA2 also exerts a negative effect on
cell proliferation, with increased expression in the placenta being
associated with intrauterine growth retardation though uteropla-
cental insufﬁciency (McMinn et al., 2006). In contrast, decreased
expression of PHLDA2 was detected in neuroendocrine tumors
relative to normal islet controls, as a downstream effect of losing
the tumor suppressor gene MEN1 resulting in Multiple Endocrine
Neoplasia type 1 (Dilley et al., 2005).
The lead SNP at this locus is within the intron of the
KCNQ1 protein-coding gene, yet the lead SNP for a putative sec-
ondary association signal is in the exon of an antisense lncRNA
(KCNQ1OT1) (Morris et al., 2012). KCNQ1OT1 is a 91 kb long
transcript encoded by RNA polymerase II and localized exclu-
sively in the nucleus (Pandey et al., 2008). In early development,
KCNQ1OT1 is expressed in a monoallelic fashion from the pater-
nal allele and has been linked to silencing of nearby genes on
the same chromosome, resulting in these genes being expressed
exclusively from the maternal allele. This is mediated through
the interaction of KCNQ1OT1 with PRC2 components and G9a
histone methyltransferase resulting in enrichment of repressive
histone modiﬁcations H3K27me3 and H3K9me3 at this locus
(Pandey et al., 2008). However, this pattern is complicated by
the lineage-speciﬁc loss of imprinting at some genes. Speciﬁcally,
KCNQ1 and KCNQ1OT1 showed developmental loss of imprint-
ing with biallelic expression in adult islets (Travers et al., 2013).
Interestingly, in the developing mouse heart, Kncq1ot1 is required
for paternal silencing of Cdkn1c and Slc22a18, but not Kcnq1
indicating that Kcnq1ot1 may be more directly involved in the
regulation of these two genes (Korostowski et al., 2012).
One proposedmodel to explain the effect of SNPs at this locus is
that risk alleles reduce KCNQ1OT1 expression, thereby decreasing
repressive histone modiﬁcations, increasing CDKN1C expression
and thereby impairing islet proliferation or development (Travers
et al., 2013). In contrast to this model, KCNQ1OT1 was reported
to be upregulated in T2D islets (Morán et al., 2012). However,
this apparent contradiction may be explained by risk SNPs hav-
ing an effect on imprinting early in development, whereas the
KCNQ1OT1 upregulation in T2D adult islets may be part of the
compensatory proliferative response of islets to hyperglycaemia.
ANRIL
CDKN2A/CDKN2B is another T2D GWAS locus containing a
well-characterized lncRNA. This locus encodes three tumor-
suppressors: p16INK4A, p14ARF , and p15INK4B. The expression of
these genes is regulated by polycomb-mediated silencing through
H3K27me3. Of particular relevance to diabetes, p16INK4A up-
regulation has been shown to be responsible age-dependent
decline in beta cell proliferative capacity (Krishnamurthy et al.,
2006). The histonemethyltransferase andPRC2 component, Ezh2,
represses p16INK4A expression in young beta cells, permitting pro-
liferation. However, declining Ezh2 levels in aging beta cells lead to
derepression of p16INK4A expression, and consequent inhibition
of proliferation (Chen et al., 2009).
The lead SNP (rs10811661) at this locus is downstream of, and
closest to the lncRNA ANRIL (CDKN2B-AS1). The lead SNP for a
putative secondary association signal (rs944801) is located within
an intron of ANRIL (Morris et al., 2012). This region (chromo-
some 9p21) has been strongly associated with susceptibility to a
number of diseases. SNPs associated with coronary disease, stroke,
melanoma and glioma are all located close to ANRIL and corre-
lated with ANRIL expression (Cunnington et al., 2010; Pasmant
et al., 2011). Although no direct mouse ortholog of ANRIL has
been reported, a lncRNA of unknown function has been detected
at the orthologous region of the mouse genome. Deletion of part
of the “9p21” orthologous region in mice (including a section
of this lncRNA) increased mortality and affected expression of
neighboring genes (Visel et al., 2010), indicating that gene regula-
tory sequences and possibly this lncRNA perform roles conserved
between human and mouse.
ANRIL interacts with both PRC1 (CBX7) and PRC2 (SUZ12)
components to affect the epigenetic regulation of gene expression
Table 2 |Type 2 diabetes susceptibility loci where a lead SNP falls within a lncRNA gene.
SNP Locus Result of combined meta analysis
(Morris et al., 2012)
Annotation closest to SNP Gene type lncRNA Name
rs2075423 PROX1 Lead SNP Non-coding exon Antisense lncRNA PROX1-AS1
rs12497268 PSMD6 Lead SNP Non-coding exon* Antisense lncRNA PRICKLE2-AS1
rs10811661 CDKN2A/B Lead SNP 13.5 kb downstream of lncRNA gene Antisense lncRNA CDKN2B-AS1 (ANRIL)
rs944801 Lead SNP for putative secondary signal Intron Antisense lncRNA CDKN2B-AS1 (ANRIL)
rs163184 KCNQ1 Lead SNP Intron Protein-coding KCNQ1
rs231361 Lead SNP for putative secondary signal Non-coding exon* Antisense lncRNA KCNQ1-OT1
rs11063069 CCND2 Lead SNP Intron Antisense lncRNA CCND2-AS1 / CCND2-AS2
SNPs reported in a meta analysis of GWA studies (Morris et al., 2012) overlapping lncRNA annotations in Ensembl (assembly GRCh38). *SNP also falls within an intron
of the protein-coding gene.
Frontiers in Genetics | Non-Coding RNA July 2014 | Volume 5 | Article 193 | 4
Pullen and Rutter Beta cell lncRNAs and diabetes
at this locus (Yap et al., 2010; Kotake et al., 2011). Competitive
inhibition of ANRIL was reported to increase p16INK4A expres-
sion resulting in decreased proliferation in ﬁbroblasts (Yap et al.,
2010). A separate depletion of ANRIL in lung ﬁbroblasts also
reported decreased proliferation, although in this case primar-
ily through upregulation of p15INK4B. The direction of this effect
ﬁts with reports of T2D SNPs being associated with decreased
ANRIL expression, although not in all populations (Cunnington
et al., 2010). It therefore appears that ANRIL recruits both PRC1
and PRC2 to this locus in a coordinated manner to repress these
proliferation inhibitors. Disruption of ANRIL expression or func-
tion by SNPs could impair silencing at this locus decreasing the
proliferative capacity of beta cell.
One should caution thatANRILmaynot be limited to cis-acting
effects, as overexpression of ANRIL in HeLa cells has also been
reported to produce genome-wide effects on gene expression (Sato
et al., 2010). An interesting direction for future research may thus
be to determine how regulation of this locus by ANRIL integrates
with the PDGF pathway responsible for age-dependent decline in
beta cell proliferative capacity (Chen et al., 2011). Whereas ectopic
expression of Ezh2 was sufﬁcient to increase beta cell proliferation
in young mice, it was unable to repress p16INK4A in older mice
without combined inhibition of trithorax group proteins (Zhou
et al., 2013). It would be of particular interest to discover whether
manipulation of ANRIL in adult beta cells can reverse this block
on proliferation, or whether its effects are primarily in developing
beta cells.
It is interesting to note that ANRIL and KCNQ1OT1 are both
expressed in numerous tissues, yet certain SNPS within them are
associated speciﬁcally with T2D susceptibility. It may be that
beta cell replication during compensation to insulin resistance
is particularly sensitive to ANRIL function meaning that these
cells are most severely affected by ANRIL variants. Alternatively,
ANRIL may be involved in beta cell-speciﬁc interactions which
are uniquely affected by T2D SNPs. While the former proposition
appears more likely, functional studies from one cell-type may not
be directly applicable to others. The lack of a clear mouse ortholog
of ANRIL has also prevented the use of mouse transgenics for
investigating its function. Further investigation into the relation-
ship between lncRNAs expressed in human andmouse at this locus
would provide valuable insight into whether mouse experiments
could be used to study ANRIL function.
lncRNAs AS THERAPEUTIC TARGETS
The discovery of lncRNAs implicated in susceptibility to, and the
progression of, T2D raises the question of whether lncRNAs can
be therapeutically manipulated to ameliorate this disease. lncR-
NAs offer a number of advantages as therapeutic targets. Firstly,
the highly cell-type speciﬁc expression pattern of many lncRNAs is
likely because they are involved in the cell-type speciﬁc regulation
of genes which themselves are more widely expressed. Manipu-
lating lncRNAs could therefore allow the effects to be speciﬁcally
targeted to a single cell-type, with few side effects.
Furthermore, lncRNAs are involved in the epigenetic regulation
of fundamental cellular processes such as pluripotency and cell
identity. Much of the protein machinery regulating the epigenetic
landscape is widely expressed, making targeting any intervention
difﬁcult. By acting as scaffolds to bring together particular combi-
nations of chromatin-modifying complexes, transcription factors,
etc. and target them to speciﬁc genomic loci, lncRNAs can pro-
vide speciﬁcity to this system. As such, lncRNAs may also provide
a speciﬁc target to inﬂuence the epigenetic landscape underlying
beta cell identity, and the potential to reinforce beta cell identity
when this is challenged by T2D.
In contrast to lncRNAs, themore clearly deﬁnedmechanisms of
miRNA processing and function have allowed greater progress to
be made towards therapeutic targeting of these short non-coding
RNAs. The most successful route has been to inhibit miRNAs
in vivo by administrating modiﬁed oligonucleotides systemically
(Montgomery and van Rooij, 2011). Although the short length
of miRNAs makes them easy to target using short complemen-
tary oligonucleotides, a similar approach termed “antagoNATs”
uses short antisense oligonucleotides to target lncRNAs. Brain-
derived neurotrophic factor (BDNF-AS) is a brain expressed NAT
which inhibits the BDNF gene. Continuous in vivo delivery to
mouse brain via an osmotic minipump stably increased BDNF
expression in a highly locus-speciﬁc effect, with a correspond-
ing increase in neurite outgrowth and differentiation (Modarresi
et al., 2012). While this form of delivery may be of limited use in
clinics, advances in delivery of other modiﬁed oligonucleotides,
such as siRNAs, will likely increase the feasibility of using this
approach more widely (Gavrilov and Saltzman, 2012). Whether
similar approaches could be used to target diabetic beta cells
relies on the identiﬁcation and characterization of islet-speciﬁc
lncRNAs with negative impacts on beta cell identity, function or
proliferation.
Therapeutic increases in miRNA function have been possible
using chemically synthesized miRNA mimics. While the mim-
ics themselves are highly effective, targeting their delivery to a
particular cell type is not. The use of adeno-associated viral
(AAV) vectors offers the possibility to target miRNA expression to
particular tissues through both viral tropism and the use of tissue-
speciﬁc promoters (Montgomery and van Rooij, 2011). Synthetic
lncRNA mimics would not be practical due to the greater length,
but viral expression approaches used for miRNAs could well be
adapted for lncRNA delivery. However, as some models propose
lncRNAs function through recruiting proteins to the nascent tran-
script, the site of expression may be critical for their functions.
Ectopic expression may not be able to recapitulate the full effects
of endogenous lncRNAs. Another concern is the stage of develop-
ment at which lncRNAs act. T2D susceptibility at the KCNQ1OT1
locus involves the imprinting, which is lost in adult beta cells, sug-
gesting that this lncRNA plays a role in beta cell development. It is
therefore possible that manipulation of KCNQ1OT1 in adult beta
cells would be unable to ameliorate any developmental defects. To
counter this view, there are a large number of lncRNAs expressed
in adult beta cells, including some only found in mature beta cells.
Furthermore, the regulation of GLIS3 by one islet lncRNA demon-
strates that signiﬁcant diabetes genes are regulated in adult beta
cells by lncRNAs (Morán et al., 2012).
CONCLUSION
The large number of highly cell-type speciﬁc lncRNAs identiﬁed
in recent years provides the potential for signiﬁcant regulation
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of gene expression and cell phenotype in pancreatic beta cells.
However, the functional characterization of these lncRNAs has
inevitably lagged behind their discovery. So far there is evidence
for the epigenetic regulation of two highly signiﬁcant T2D loci by
lncRNAs. In addition there is more circumstantial evidence that a
number of further lncRNAs are associated with beta cell develop-
ment and function. Whether lncRNA expression changes during
beta cell compensation to insulin resistance, potentially playing
a role in beta cell expansion under these conditions, is also an
important area for investigation, and may reveal the potential for
therapeutic targeting. Further detailed investigation of the speciﬁc
lncRNAs involved in this process are required to reveal the true
extent to which lncRNAs regulate beta cell identity, proliferation
and function.
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